XBB.1.5 Omicron Subvariant + FDA Approves AstraZeneca’s New Asthma Inhaler

In this week’s episode, Ayesha discussed the new Omicron subvariant XBB.1.5, also known as Kraken, which is rapidly circulating in parts of the US. It is the most transmissible variant yet and is highly immune evasive. COVID-19 cases have been on the rise in the country, including significant increases in hospitalizations and deaths. While XBB.1.5 has been found in dozens of other countries now, cases remain low around the world. Hear more about the new subvariant and why scientists are keeping a close eye on it.

Ayesha also talked about the FDA approval of AstraZeneca’s asthma inhaler Airsupra, the first-in-class drug that contains both a beta agonist and corticosteroid. The inhaler is approved as a rescue medication for adults with asthma to help treat bronchoconstriction and asthma attacks. It’s the first inhaler that both treats symptoms and the underlying causes of an attack by targeting inflammation of the airways.

Read the full articles here:

XBB.1.5 Omicron Subvariant Being Closely Watched as Most Transmissible Variant Yet

AstraZeneca’s Airsupra Approved as First-In-Class Combo Asthma Treatment

For more life science and medical device content, visit the Xtalks Vitals homepage.

Follow Us on Social Media

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured